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Mechanism of erosion of nanostructured porous
silicon drug carriers in neoplastic tissues
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Nanostructured porous silicon (PSi) is emerging as a promising platform for drug delivery
owing to its biocompatibility, degradability and high surface area available for drug loading.
The ability to control PSi structure, size and porosity enables programming its in vivo
retention, providing tight control over embedded drug release kinetics. In this work, the
relationship between the in vitro and in vivo degradation of PSi under (pre)clinically relevant
conditions, using breast cancer mouse model, is deﬁned. We show that PSi undergoes
enhanced degradation in diseased environment compared with healthy state, owing to the
upregulation of reactive oxygen species (ROS) in the tumour vicinity that oxidize the silicon
scaffold and catalyse its degradation. We further show that PSi degradation in vitro and in vivo
correlates in healthy and diseased states when ROS-free or ROS-containing media are used,
respectively. Our work demonstrates that understanding the governing mechanisms
associated with speciﬁc tissue microenvironment permits predictive material performance.
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T
he beneﬁts of localized delivery of therapeutic agents serve
as a driving force for the design and synthesis of
biomaterials for medical applications1–3. The demands
from these materials are high, as they must be biocompatible and
exert desired therapeutic effect by controlling their structure,
morphology and physicochemical properties. Degradable
biomaterials that perform their function and are then
eliminated from the body are of high interest as permanent
residence time of devices and chronic inﬂammation were found
to correlate4–8. Erosive materials are dynamic; they change shape,
morphology and structure in the same time frame they exert their
desired effects. Furthermore, when considering the release of
embedded drugs, any change in material fate as a result of speciﬁc
microenvironmental impositions would affect not only material
performance and potentially tissue response, but also drug-release
kinetics. We have shown that material degradation depends on
formulation, shape and implantation site9. As biodegradability
and biocompatibility are contextual and not a constitutive
property of the material, they can only be determined within
speciﬁc environments. This then needs to be put in the
perspective of the speciﬁc clinical scenario and the environment
the material will be exposed to. Neoplastic states are one example
in which a range of modiﬁcations including extracellular matrix
content, immune cells, enzymes and reactive oxygen species
(ROS) may modify device fate. Thus, comparison between
material erosion in vivo in healthy and diseased states is
crucial for elucidating the importance of the physiological
microenvironment in determining device performance, tissue
response and eventually clinical outcome. This will then help
isolating and identifying the precise in vitro conditions that
represent the most critical parameters determining material
behaviour in vivo.
Nanostructured porous silicon (PSi) is a promising and
versatile material for biomedical applications10. The high
tunability of PSi-based scaffolds, imparted by the ability to
tailor the porosity and surface chemistry11–13, together with the
biocompatibility and degradability into nontoxic orthosilicic
acid14,15, has already led to the use of PSi as
optical biosensors16–18, for biomolecular screening19, tissue
engineering20–22 and drug delivery11,12,23–29, speciﬁcally in
cancer therapy12,26,30–35. Although PSi emerges as a promising
vehicle for local drug release, its in vivo fate was not yet studied,
and to the best of our knowledge there is no mechanistic study
that examines the potential impact of tissue microenvironment
on PSi degradation. We hypothesized that pathological state, such
as breast cancer, would alter PSi fate in vivo. As material
degradation will determine drug-release kinetics, the implications
are that the tumour state will be directly regulated by material
erosion kinetics.
In this study, we examine the effect of local pathology on PSi
fate using human breast cancer xenograft model and ﬁnd that
PSi erosion is highly catalysed in the cancerous environment
compared with the healthy state owing to the upregulation of
ROS. We exploit a noninvasive imaging technique to monitor the
fate of ﬂuorescently labelled PSi microparticles in vivo in healthy
and diseased environments. The ﬂuorescence of the reporter is
quenched by the PSi to an extent dependent on the state of
oxidation and extent of degradation. This phenomenon by itself is
indicative of the differences between healthy and diseased
environments, and in particular the impact of oxidative stress
on implanted materials. Owing to the modiﬁcation of the reporter
by the environment, we generated a formula that converts
ﬂuorescence to mass under artiﬁcial in vitro conditions that
mimic the in vivo environment. The formula is created by
tracking in vitro material fate using inductively coupled plasma
atomic emission spectroscopy (ICP-AES) and ﬂuorescence
simultaneously, and is then used to convert the in vivo
ﬂuorescence to mass. We then show that correlation between
in vitro and in vivo material erosion persists only under in vitro
clinically relevant conditions that capture the main factors
determining material fate in vivo. The ability to determine and
predict material fate in vivo under speciﬁc environments is the
next step in material design that would lead to faster and
successful clinical translation.
Results
Tracking PSi erosion in vivo. Real-time monitoring of material
erosion is a key factor in designing and programming the
performance of erodible biomaterials. However, traditional
determination of in vitro erosion cannot always predict in vivo
performance because of the signiﬁcant differences in environ-
mental forces in vitro and in vivo. As such, loss of material
integrity, structure and eventually mass may differ dramatically,
affecting in vivo biomaterial performance. Speciﬁcally, the per-
formance of nanostructured PSi-based drug delivery systems is
critically dependent on the degradation behaviour of the Si
scaffold11,33,36–38.
We studied the degradation proﬁle of nanostructured PSi thin
ﬁlms that were fabricated by anodization process at a constant
current density of 15mA cm 2 for 225 s. The etching conditions
were adjusted to yield an B2,500-nm-thick porous layer
(porosity of 65% and surface area of B450m2g 1) with a
typical morphology of interconnecting cylindrical pores. Follow-
ing the electrochemical etching, the resulting porous ﬁlms were
lifted off from the bulk Si substrate, by applying an electro-
polishing current, after which the freestanding ﬁlms were
fractured into micron-size particles (2–18 mm) by ultrasonication
(see Supplementary Fig. 1a,b).
Most studies have investigated the behaviour of these carriers
in vitro; however, future clinical applications of these nanoma-
terials would require characterizing material in vivo erosion and
establishing clinically relevant in vitro conditions under which
one can attain similar behaviour in the two domains. Monitoring
PSi degradation noninvasively and continuously is challenging.
Gu et al.39 have studied the in vitro degradation and dissolution
process of luminescent PSi particles and suggested that material
fate can be monitored through its intrinsic luminescence. We
found that the luminescent signal of the particles is not sufﬁcient
post implantation, thus requiring another method for in vivo
tracking to be employed (Supplementary Fig. 2).
To allow optical monitoring of the in vivo degradation process,
PSi microparticles were chemically modiﬁed by thermal hydro-
silylation of undecylenic acid26,38,40,41 to enable covalent
attachment of Texas-red hydrazide (TRH) dye molecules to the
Si scaffold, as illustrated in Supplementary Fig. 1c. Attenuated
total reﬂectance Fourier-transform infrared (ATR-FTIR)
spectroscopy was used to conﬁrm the chemical modiﬁcation of
the Si scaffold following thermal hydrosilylation and ﬂuorophore
tagging (Supplementary Fig. 1c).
Figure 1a schematically illustrates the erosion process of the
TRH-labelled PSi microparticles. Many studies have shown that
the degradation of PSi in physiological media involves the
oxidation of the Si scaffold into Si-dioxide, followed by the
hydrolysis of the Si–O bonds to release soluble orthosilicic acid
species11,14,37,38,42. In the case of TRH-labelled PSi, as the
ﬂuorophore molecules are covalently attached to the Si backbone,
their release into the surrounding media can occur only through
the degradation of the crystalline Si scaffold. Thus, Si erosion can
be monitored by measuring the ﬂuorescence intensity of the
aqueous media, into which the Si–TRH species were released, as
corroborated by the analytical quantiﬁcation of the content of Si
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in the release media using ICP-AES, for TRH-labelled PSi
microparticles (Fig. 1b). This assay is commonly used to provide
the absolute values of mass changes in the Si matrix and is
considered the gold standard method for characterizing PSi
degradation32,33,36,43,44. The ICP-AES and ﬂorescence analyses
highly correlate (R2¼ 0.993, Fig. 1b inset) and display a gradual
decrease in the Si mass loss, resulting in a complete degradation
of the microparticles within B20 days. These results reveal
that ﬂuorescence tracking enables sensitive monitoring of PSi
degradation process.
The effect of the tumour microenvironment on PSi erosion. In
order to provide insight into the effect of the physiological
microenvironment and disease state on the erosion of the PSi
carriers, material mass loss in vivo was monitored by intravital
tracking of the ﬂuorescently tagged microparticles. Breast cancer
tumours were induced by injecting luciferase-expressing human
breast carcinoma cells (luc-MDA-MB-231) into the left
mammary fat pad of severe combined immunodeﬁciency mice.
These cells were engineered to express luciferase, thus enabling
noninvasive imaging of tumour state by quantifying the
bioluminescent signal using the in vivo imaging system, see
Supplementary Fig. 3. Following tumour induction, intratumoral
injections of TRH-PSi microparticles (aliquots of 2mg of particles
in 30 ml) were administered and intravital tracking was carried
out to visualize and quantify the ﬂuorescence of the labelled
particles for 11 days. Similar doses of particles were injected into
mammary tissues of healthy mice and monitored in parallel.
Distinct differences between Si degradation in healthy and
diseased mice are evident, revealing the profound effect of the
physiological microenvironments on PSi erosion (Fig. 2a).
Interestingly, while one expects to see a decrease in ﬂuorescence
as a result of degradation, an increase in ﬂuorescence is observed
at early time points. TRH-PSi injected intratumorally display
signiﬁcantly higher ﬂuorescent intensity compared with particles
implanted into healthy mammary tissue throughout the timescale
of the experiments. Intratumorally injected particles show rapid
increase in ﬂuorescence intensity reaching a maximum value on
day 5 (5.5-fold increase), followed by a fast decrease, in contrast
to a more attenuated response in healthy state (2.5-fold increase
by day 9, Fig. 2b).
Similar behaviour of labelled PSi was recently demonstrated in
ref. 38 in vitro. It was found that the ﬂuorescence intensity of dye
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Figure 1 | Degradation of TRH-labelled PSi microparticles. (a) Schematics
of the degradation process of TRH-labelled PSi microparticles and
(b) in vitro Si degradation proﬁles measured by ICP-AES (blue) and TRH
ﬂuorophore release (red). Data are the average percentage±s.d of three
independent experiments. Note: the porous nanostructure is characterized
by a morphology of interconnecting cylindrical pores that is not reﬂected in
the schematic representation of the PSi.
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Figure 2 | Fluorescence intensity of TRH-labelled PSi particles in healthy and tumour-bearing mice. (a) Representative measurements using the in vivo
imaging system technique and (b) analysis of the results. (c) Schematics of ﬂuorophore signal in the presence of tumour ROS. Data are the average
percentage±s.d of two independent experiments, each including 15 severe combined immunodeﬁciency (SCID) female mice (10 mice were induced with
breast cancer and 5 served as a healthy control).
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molecules attached to the surface and inner pore walls of
mesoporous Si particles depends on the oxidation level of the Si
scaffold. When ﬂuorescent dye molecules are attached to freshly
etched PSi, low levels of ﬂuorescence are observed because of
quenching of the emitted light by the highly dense electrons in the
PSi semiconductor nanostructure45–49. As the PSi nanostructure
oxidizes, the growing oxide layer facilitates physical separation
between the dye donor and the semiconductor acceptor, thus
eliminating the quenching phenomenon. This process attenuates
energy transfer and results in higher ﬂuorescence emission38,50.
We hypothesized that the observed differences in the
ﬂuorescence intensity of TRH-PSi microparticles injected into
healthy and cancerous tissues can be ascribed to the profound
differences between the physiological microenvironments as
related to ROS concentration and the resulting oxidative stress51.
We conﬁrmed the elevation in ROS concentration in the tumour
microenvironment using ROS-sensitive ﬂuorophore in healthy
and cancerous tissues. This ﬂuorophore is optically silent until the
attached quenching molecule is cleaved by interacting with an
oxidant like ROS, permitting ﬂuorescence emission. High signal is
observed in the tumour region, indicative of ROS upregulation,
compared with the relatively low signal detected in healthy mice
(see Supplementary Fig. 4). The pronounced elevation in ROS
concentration in the tumour microenvironment52 may induce a
faster build up of the Si oxide layer compared with the marginal
and sustained oxidation in healthy state. Hence, in the diseased
environment the quenching phenomenon is eliminated, enabling
tracking the changes in ﬂuorescence signal as the PSi degrades, as
schematically illustrated in Fig. 2c.
Identifying physiological conditions deﬁning in vivo behaviour.
We hypothesized that the in vivo erosion of PSi in healthy and
tumour environments, as reported by the ﬂuorophore, is a result
of two mechanisms: the actual degradation of the Si scaffold and
also the modiﬁcation of the reporter’s signal by the build up of the
oxide layer that further modiﬁes the degradation53. In order to
elucidate the contribution of each mechanism, we constructed
artiﬁcial conditions in vitro that allow for controlled addition
of physiologically relevant ROS concentrations to examine the
impact of ROS on PSi degradation. Once able to eliminate the
effect of the environment on the ﬂuorophore signal, we will be
able to convert ﬂuorescence signal to mass loss. However, as
the cancerous microenvironment presents additional disparities
beyond ROS upregulation compared with the healthy state, we
examined the impact of other possible factors on PSi degradation
in vitro, including acidic pH (6.5 compared with 7.4) and addition
of proteins whose adsorption to PSi particles following their
in vivo administration may alter the PSi degradation proﬁle. The
degradation was monitored in vitro using PBS or human serum,
at pH 6.5 or 7.4, with or without ROS present and their
combinations (see Supplementary Fig. 5). PSi degradation proﬁle
under each of these conditions was similar, unless ROS was used,
the latter leading to signiﬁcant acceleration in degradation. These
experiments support our hypothesis that the determinant factor
accelerating PSi erosion in the tumour microenvironment
is ROS upregulation. Speciﬁcally, 3-morpholinosydnonimine
N-ethylcarbamide (SIN-1) was used to generate physiologically
relevant levels of peroxynitrite (OONO ; refs 38,54,55), a highly
reactive oxygen species involved in human carcinogenesis56.
Figure 3 summarizes the in vitro effect of PBS with and without
peroxynitrite on the ﬂuorescent intensity of TRH-PSi
microparticles in comparison with their in vivo behaviour,
observed in healthy and cancerous tissues. The initial increase
in ﬂuorescence intensity of the particles by a factor of 4.7 up to
day 5 (Fig. 3a) followed by a fast signal reduction is recapitulated
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Figure 3 | In vivo and in vitro measurements of the ﬂuorescence intensity
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were induced with breast cancer and 5 served as a healthy control).
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in vitro by adding the oxidizing agent OONO to the
degradation media. A linear correlation between the
ﬂuorescence signal in vitro and in vivo (R2¼ 0.796) is attained
under these conditions. Control in vitro experiments with PBS
show a marginal increase in ﬂuorescence (Fig. 3b) and poor
correlation with in vivo behaviour in cancerous tissue
(R2¼ 0.076). However, this in vitro behaviour (in the presence
of PBS) correlates with in vivo ﬂuorescence when particles are
injected into healthy tissue with low oxidation levels (Fig. 3c,
R2¼ 0.860), thus corroborating our hypothesis that oxidative
stress is a key factor determining PSi in vivo erosion. These results
reveal that traditional in vitro assessment of particles’
ﬂuorescence using PBS buffer is not indicative of in vivo
behaviour in diseased tissues, emphasizing the importance of
developing preclinically relevant in vitro conditions under which
one can attain similar behaviour in vitro and in vivo.
Generating a formula to convert ﬂuorescence to mass loss.
While the presence of ROS modiﬁes the signal of our reporting
molecule, it is also expected to enhance the degradation of PSi, as
PSi degradation in aqueous solutions involves oxidation of Si to
Si-dioxide, followed by the hydrolysis of Si–O bonds to release
orthosilicic acid38. Thus, elevated levels of ROS will accelerate the
degradation of intratumorally injected particles, resulting in
signal reduction. To isolate the autocatalytic effect of enhanced
degradation with ampliﬁed oxidation while excluding the effect
on the ﬂuorescent reporter molecule, in vitro Si mass loss of
TRH-PSi microparticles was quantiﬁed using the ICP-AES
analysis under physiologically relevant levels of peroxynitrite
(Fig. 4a). While this method is vastly used to accurately monitor
Si erosion in vitro and in vivo12,32,44,57,58, it requires killing
animals at each time point of the experiment in order to
determine the Si content in the tissue. However, this method
allows us to compare in vitro erosion under artiﬁcial conditions
without ‘contaminating’ the proﬁle with other parameters that do
affect the ﬂuorescent reporter. Indeed, Si erosion measured with
ICP-AES is enhanced in the presence of ROS, resulting in
complete degradation of the microparticles within 10 days.
In comparison, the erosion proﬁle in PBS depicts a gradual
degradation, lasting for B20 days (Fig. 4a). This ﬁnding
corroborates that the acceleration of Si degradation is a result
of oxidative stress, and not a simple modiﬁcation of the reporters’
signal. Si mass is presented on a modiﬁed log-linear scale as the
erosion proﬁles ﬁt exponential decay36 (Fig. 4b). A linear ﬁt to
the data reveals enhanced erosion rate in the presence of
physiologically relevant levels of peroxynitrite compared with
PBS only, with erosion rate constants of k¼ 0.183 and 0.115 per
day for the OONO solution and PBS, respectively.
Calculating Si in vivo erosion. The excellent correlations
between PSi in vitro and in vivo ﬂuorescence, both in healthy and
diseased states (Fig. 3), suggest that we can use the conversion
between ﬂuorescence and mass loss generated in vitro (see
Supplementary Fig. 6) to convert Si in vivo mass loss from in vivo
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ﬂuorescence. Figure 5a presents in vivo Si mass loss calculated for
the labelled microparticles in healthy and tumour environments.
The PSi in vivo erosion rate is signiﬁcantly enhanced in the
tumour environment compared with the healthy state, with
k¼ 0.209 and k¼ 0.112 per day (Fig. 5b), respectively.
Establishing these correlations allows for the assessment of in vivo
Si mass loss proﬁles while eliminating the need to kill animals
at each time point of the experiments, presenting a generic
methodology to infer device performance noninvasively and
directly from the observed in vivo ﬂuorescence. It is worth
mentioning that PSi in vivo degradation kinetics can be tuned by
changing particle size and porosity, but will be further modiﬁed
as a function of the injection dose/site and tumour type. Hence,
our approach of examining PSi microparticles in light of their
speciﬁc clinical application and the environment they would be
exposed to should be employed to unravel the impact of the
physiological microenvironment on material performance.
In summary, this work demonstrates that material perfor-
mance is contextual and hence should be studied in light of the
intended clinical use. PSi has emerged as a material with high
clinical potential as its high surface area provides ample
opportunities for loading drugs and molecules for therapeutic
beneﬁts. Although PSi degradation largely determines the release
of embedded drugs, its erosion proﬁle under pathological states
that are of clinical relevance was not studied. Understanding the
factors affecting PSi erosion in vivo would facilitate its rapid
development and clinical usage as a drug carrier. We now show
that PSi erosion is enhanced in the tumour microenvironment
compared with the healthy state as a result of elevation in
oxidative stress, see Fig. 2. The relationship between ﬂuorescence
intensity used to monitor PSi in vivo erosion and Si mass with
time is complex and is being affected by ROS content in the Si
milieu, as we show in Fig. 3. Using ICP-AES as a method to track
in vitro Si degradation together with optical imaging used to
monitor in vitro and in vivo Si ﬂuorescence, we were able to
convert the complex ﬂuorescent signal into material mass. This
approach enables noninvasive and continuous tracking of PSi
erosion with time. PSi erosion almost doubled in the cancerous
tissue, highlighting the need to examine materials in light of their
clinical application (Fig. 5). This approach should be applied to
any material and clinical scenario to attain predictive perfor-
mance. Speciﬁc clinical scenarios may require further material
optimization but would facilitate successful clinical outcome and
translation of new materials to the clinic.
Methods
Fabrication and characterization of porous Si carriers. Fabrication of PSi
microparticles. Mesoporous Si ﬁlms are fabricated from single-side polished
pþ o1004 silicon wafers (B1mO-cm, B-doped, from Siltronix Corp, France)
using an electrochemical etch process, in a 3:1 (v/v) solution of aqueous HF (48%,
Merck, Germany) and ethanol (99.9%, Merck), at a constant current density of
15mA cm 2 for 225 s. Si wafers with an exposed area of 6.16 cm2 are contacted on
the backside with an aluminium foil and mounted in a Teﬂon-etching cell;
a platinum spiral coil is used as the counterelectrode. After etching, the surface of
the wafer is rinsed with ethanol several times and dried under a dry nitrogen gas.
The resulting porous ﬁlms are removed from the bulk Si substrate by applying an
electropolishing current density of 4mA cm 2 for 3min in an electrolyte solution
of 3.3% HF in ethanol. The freestanding ﬁlms are then placed in absolute ethanol
and ultrasonically fractured, using an ultrasonic probe (Amp. 55%, 30min,
Vibracell 750W, Sonics, USA), to produce particles ranging in size from 2 to
18mm. All materials are supplied by Sigma Aldrich Chemicals, unless otherwise
mentioned.
Hydrosilylation of PSi microparticles. Freshly etched PSi microparticles are
chemically modiﬁed using thermal hydrosilylation of undecylenic acid (Z95%),
using microwave irradiation (Intelowave MS-204WS LG), to form undecanoic
acid-terminated (u-PSi) PSi. Brieﬂy, 20mg of microparticles are placed in an open
Pyrex beaker containing 6ml of undecylenic acid and are allowed to react for 6min
at 320W. The resulting microparticles are thoroughly rinsed with acetone
(Frutarom, Israel) and ethanol (99.9%, Merck) to remove unreacted species from
the surface and then dried under a stream of nitrogen gas.
Physical characterization of PSi microparticles. High-resolution scanning
electron microscopy is performed using a Carl Zeiss Ultra Plus Field Emission
scanning electron microscopy, at an accelerating voltage of 1 keV. Particle size and
size distribution are determined using confocal laser scanning microscopy (LSM
700, Carl Zeiss, Germany) and the image analysis software (Axio Vision Rel. 4.8
with auto-measurement module). Surface chemistry of the microparticles was
characterized with ATR-FTIR spectroscopy using a Thermo 6700 FTIR instrument
equipped with a Smart iTR diamond ATR device.
Fluorescence labelling of porous Si microparticles. Twenty milligrams of
undecylenic acid modiﬁed (u-PSi) microparticles are suspended in 2.5ml of 0.2M
solution of N-(3-dimethylaminopropyl)-N2-ethylcarbodiimide hydrochloride
(Z98.0%), and 2.5ml of 0.1M solution of N-Hydroxysulfosuccinimide sodium salt
(Sulfo NHS, Z98.0%) for 10min. TRH solution (2.5ml; Invitrogen, USA), con-
sisting of 1.62 10 3M TRH in N,N-Dimethyl formamide (Frutarom), is added
and the microparticles allowed to react under orbital shaking for 2 h at room
temperature. Removal of unreacted TRH following labelling involved cycles of
centrifugation (15,000 g for 5min) and replacement of the supernatant with
N,N-Dimethyl formamide and deionized water. This step is repeated several times
till the red colour of TRH had disappeared, after which the microparticles are dried
under a stream of nitrogen gas.
The in vitro effect of PBS with and without peroxynitrite on the ﬂuorescent
intensity of TRH-PSi microparticles (reported in Fig. 3) is studied by incubating
batches of 2mg of TRH-labelled particles in 2ml of PBS or PBS supplemented with
2mM SIN-1, under orbital agitation of 100 r.p.m. at 37 C. At designated time
intervals, each batch of microparticles is separated from the media by
centrifugation and the microparticles are placed within black well and clear bottom
96 plates, after which their ﬂuorescence is determined by high-throughput
screening using IN Cell Analyzer 2000 (GE Healthcare). Fluorescence images of the
labelled particles are captured using an excitation ﬁlter wavelength of 530–580 nm
and an emission ﬁlter wavelength of 600–660 nm and acquired automatically with a
 10 objective. Area and the mean ﬂuorescence intensity per pixel of each labelled
microparticle and the number of microparticles are obtained using the IN Cell
Developer software (GE Healthcare). Using this technique, every measurement
captured the ﬂuorescence of B5,000 microparticles directly, eliminating any
background signal that may arise from dye release to the media.
In vitro degradation. In vitro degradation is followed by tracking TRH ﬂuores-
cence intensity over time following the incubation of 2-mg TRH-labelled particles
in 2ml of PBS, under orbital agitation of 100 r.p.m. at 37 C. At designated time
intervals, aliquots are sampled and replaced with fresh PBS. TRH solutions are
separated from the microparticles by centrifugation. Concentrations of the samples
are determined by measuring the ﬂuorescence intensity of the released dye using a
microplate reader (Varioskan Flash; Thermo Scientiﬁc, Waltham, MA, USA) with
an excitation of 585 nm. The peak intensity of TRH was found to be at 602 nm, and
a calibration curve for the dye in PBS was used to determine the amount of dye
released.
The effect of ROS on Si erosion in vitro. To evaluate Si degradation kinetics,
2mg of TRH-PSi microparticles were incubated in 2ml of PBS or PBS supple-
mented with SIN-1 (2mM), under orbital agitation of 100 r.p.m. at 37 C. At
designated time intervals, aliquots were sampled and replaced with fresh PBS or
SIN-1 solution. The resulting liquid was stored at 4 C for later analysis of total
silicon by Varian Vista-Pro Inductively Coupled Plasma Atomic Emission Spec-
trometer (Varian Inc. Santa Clara, CA, USA; ICP-AES). The Si atomic emission
peaks at 212.4, 251.6 and 288.2 nm are monitored. Si erosion is expressed as
percentage of the total Si content of the studied PSi microparticles. Rate of erosion
is characterized by an exponential decay model in the form of mSi(t)¼mN[1
exp( kt)], where mN is the mass as t-N and k is a constant that characterizes
the rate of erosion.36
Breast cancer mouse model development and quantiﬁcation of Si erosion.
MDA-MB-231 Luciferase-expressing cells are used to induce breast cancer tumour
following their culture in high-glucose DMEM medium (Lonza, USA) supple-
mented with 10% FBS (Gibco, USA), 1% PS/G (Lonza) and 0.7mgml 1 G418
(Sigma, USA) for positive selection. Upon reaching the required concentration, the
cells are prepped for animal injection in HBSS (Lonza). Fifteen severe combined
immunodeﬁciency female mice (Charles River, USA) were used (10 mice are
induced with breast cancer and 5 serve as a healthy control), and the procedures
approved by the Committee on Animal Care at the Massachusetts Institute of
Technology. Each mouse is injected with 5 106 cells in 50ml, in the left mammary
fat pad. Following tumour induction, mice are monitored for tumour development
by imaging the Luciferase-expressing cells 15min following intraperitoneal injec-
tion of luciferin solution using an In Vivo Imaging System (Perkin Elmer, USA).
Tumour is also measured physically with a caliper. When the tumour reaches a
volume of B70mm3, 2mg of ﬂuorescently labelled PSi microparticles in 30 ml of
HBSS are injected intratumorally. Simultaneously, similar doses of particles are
injected into healthy mammary tissues of ﬁve healthy mice. PSi erosion is mon-
itored by tracking the ﬂuorescent signal of labelled particles using the spectral
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unmixing protocol in order to subtract background and tissue autoﬂuorescence
(Ex ﬁlters: 500–570, Em ﬁlters: 600–660). Mice are imaged until tumour reached a
volume of 1,000mm3.
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